Prevalence of thrombocytopenia in chronic hepatitis c patients arriving in out patient department
DOI:
https://doi.org/10.61581/MJSP.VOL06/01/09Keywords:
Chronic Hepatitis, Hepatitis, Hepatitis C, platelets, thrombocytopeniaAbstract
Objective: To determine the prevalence of thrombocytopenia in chronic Hepatitis-C patients presenting at the outdoor patients department of Farooq Hospital, Lahore.
Methodology: A Cross-sectional study was conducted in the medical outdoor patients department of Farooq Hospital, Lahore, from September 1st, 2023, to August 31st, 2024. Four hundred patients with hepatitis who were either newly diagnosed or taking treatment for the last 3 months and those who had relapse/failure to treatment were enrolled. After recording the baseline, their blood samples for serum platelet counts were withdrawn. Thrombocytopenia was labeled based on platelet counts of ?150,000 uL. The prevalence of thrombocytopenia was presented as frequency and percentage.
Results: The mean age of patients was 41.18±6.51 years. There were 271 (67.7%) males. Diabetes, hypertension, and I.H.D. were found in 54 (13.5%), 69 (17.3%), and 29 (7.3%) patients. The mean duration since hepatitis C of the patients was 6.63±1.99 months. The mean platelet count of the patients was 160.77±62.46 ×(103/uL), and there were 151 (37.8%) patients had ?150 platelet count. Thrombocytopenia was severe in 16 (10.6%) patients, moderate in 92 (60.9%) patients and mild in 43 (28.5%) patients. Since Hepatitis C was diagnosed, the mean duration was greater in severe thrombocytopenia than in mild and moderate thrombocytopenia (p<0.001).
Conclusion: Thrombocytopenia is a marker of severity in patients with hepatitis C, depicting its extrahepatic manifestation. The percentage of severe thrombocytopenia was higher in patients with longer durations, with features of cirrhosis.
Downloads
References
1. Raadsen M, Du Toit J, Langerak T, van Bussel B, van Gorp E, Goeijenbier M. Thrombocytopenia in virus infections. J Clin Med [Internet]. 2021;10(4):877. Available from: http://dx.doi.org/10.3390/jcm10040877
2. Nilles KM, Flamm SL. Thrombocytopenia in chronic liver disease: new management strategies. Clinics in liver disease. 2020;24:437–51.
3. Fierro-Angulo OM, González-Regueiro JA, Pereira-García A, Ruiz-Margáin A, Solis-Huerta F, Macías-Rodríguez RU. Hematological abnormalities in liver cirrhosis. World J Hepatol [Internet]. 2024;16(9):1229–44. Available from: http://dx.doi.org/10.4254/wjh.v16.i9.1229
4. Huang CE, Chang JJ, Wu YY, Huang SH, Chen WM, Hsu CC, et al. Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection. Biomed J [Internet]. 2022;45(5):788–97. Available from: http://dx.doi.org/10.1016/j.bj.2021.09.001
5. Rawi S, Wu GY. Pathogenesis of thrombocytopenia in chronic HCV infection: A review. J Clin Transl Hepatol [Internet]. 2020;8(2):184–91. Available from: http://dx.doi.org/10.14218/JCTH.2020.00007
6. Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJF, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol [Internet]. 2022;7(8):724–35. Available from: http://dx.doi.org/10.1016/S2468-1253(22)00050-4
7. Saleem U, Aslam N, Siddique R, Iqbal S, Manan M. Hepatitis C virus: Its prevalence, risk factors and genotype distribution in Pakistan. Eur J Inflamm [Internet]. 2022;20:1721727X2211443. Available from: http://dx.doi.org/10.1177/1721727x221144391
8. Jalan R, D’Amico G, Trebicka J, Moreau R, Angeli P, Arroyo V. New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. J Hepatol [Internet]. 2021;75 Suppl 1:S14–26. Available from: http://dx.doi.org/10.1016/j.jhep.2021.01.018
9. Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, et al. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg [Internet]. 2021;84(4):637–56. Available from: http://dx.doi.org/10.51821/84.4.015
10. Mokhles MA. Extrahepatic manifestations of HCV where do we stand? Med Clín (Engl Ed) [Internet]. 2024;162(5):231–7. Available from: http://dx.doi.org/10.1016/j.medcle.2023.10.014
11. Mansoor M, de Glanville WA, Alam R, Aslam K, Ahmed M, Isaakidis P, et al. Correction: Prevalence and risk factors for hepatitis C virus infection in an informal settlement in Karachi, Pakistan. PLOS Glob Public Health [Internet]. 2024;4(1):e0002897. Available from: http://dx.doi.org/10.1371/journal.pgph.0002897
12. Kashif AA, Bakhtawar B, Akhtar A, Akhtar S, Aziz N, Javeid MS. Treatment response prediction in hepatitis C patients using machine learning techniques. Int J TIM [Internet]. 2021;1(2):79–89. Available from: http://dx.doi.org/10.54489/ijtim.v1i2.24
13. Gasmi B, Kleiner DE. Liver histology: Diagnostic and prognostic features. Clin Liver Dis [Internet]. 2020;24(1):61–74. Available from: http://dx.doi.org/10.1016/j.cld.2019.09.004
14. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol [Internet]. 2007;13(17):2436–41. Available from: http://dx.doi.org/10.3748/wjg.v13.i17.2436
15. Zubair T, Israr S, Uddin S. Haematological Presentation in Hepatitis-C Infection. Ophthalmology Update. 2016;14.
16. Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology [Internet]. 2022;76(1):139–54. Available from: http://dx.doi.org/10.1002/hep.32341
17. Iman NU, Khan H. Thrombocytopenia in chronic liver disease due to hepatitis C virus. RMJ. 2009;34(1):72–4.
18. Rehman S, Rahman S, Khan S, Ahmad N, Rahman N. Frequency of thrombocytopenia in hepatitis C patients. Journal of Medical Sciences. 2019;27(3):190–3.
19. Ali N, Ahmed N, Khan RT, Haq MM, Memon HL, Mangnejo GM, et al. Improvement in Thrombocytopenia after Direct Acting Anti-Viral (DAA) Therapy in Patients with Hepatitis C Virus-Related Chronic Liver Disease in Pakistani Population-A Single Centered Study. Journal of Health and Rehabilitation Research. 2024;4(2):59–64.
20. Shah I, Munib N, Badshah A, Mohammad W. Frequency of Sustained Virologic Response in Hepatitis C Positive, Treatment Naïve Patients on Sofosbuvir and Daclatasvir. Journal of Gandhara Medical and Dental Science. 2023;10(3):22–6.
21. Abbas M, Sardar J, Asim M, Khan R, Khan S, Jaffar G. Frequency of thrombocytopenia in patients with chronic liver diseases in Tertiary care hospital. Pakistan Journal of Medical and Health Sciences [Internet]. 2022;16(1):739–41. Available from: http://dx.doi.org/10.53350/pjmhs22161739
22. Merza MA, Taha SK, Ibrahim SM, Sadeeq AT, Abdulrahman MR. Significant association of thrombocytopenia with chronic active hepatitis B virus infection in a tertiary care hospital of an intermediate prevalence HBV country. Asian J Med Biol Res. 2019;5(3):207–11. Available from: http://dx.doi.org/10.3329/ajmbr.v5i3.43589
23. Rauber P, Lammert F, Grotemeyer K, Appenrodt B. Immature platelet fraction and thrombopoietin in patients with liver cirrhosis: A cohort study. PLoS One. 2018;13(2):e0192271. Available from: http://dx.doi.org/10.1371/journal.pone.0192271
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Haris Raza, Abdul Shakoor Shakir, Awais Amin, Rizwan Zafar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
